Faculty

Jingsong Bian
Professor
Department Head of Pharmacology
bianjs@sustech.edu.cn

Self-introduction

Dr. Jinsong Bian is a full Professor and acting chair in the Department of Pharmacology, School of Medicine, Southern University of Science and Technology (SUSTech). Before joining in SUSTech, Dr. Bian was first appointed as an assistant professor (2003-2008) and then an Associate Professor with tenure (2009-2020) in the department of Pharmacology, Yong Loo Ling School of Medicine, National University of Singapore, Singapore. He also served as the deputy director of Drug Development Unit of National University of Singapore (NUS) and the Research Director of Department of Pharmacologoy, Yong Loo Lin School of Medicine, NUS in the period of 2016-2020.

Dr Bian earned his PhD degree from the University of Hong Kong and was awarded with the Dr KP Stephen Chang Gold Medal for the outstanding performance in the degree of Doctor of Philosophy in 2000.  Dr Bian then went on to complete his post-doctoral training under an American Heart Association Fellowship at the Albert Einstein College of Medicine in New York, USA in 2003.

Dr Bian is an Associate Editor, lead guest editor and reviewing editor of 13 international journals, including Antioxidant Redox Signalling, Journal of Alzheimer’s Disease, Frontiers in Pharmacology. He has served as a panel member of the Singapore National Medical Research Council (since 2007) and is also a consultant Member of the Greece Society of Studying Cardiovascular Diseases (SOS-CVD) (since 2010). He serves as an advisory committee member of different societies or conferences, including the International and European Conferences on the Biology of Hydrogen Sulphide, and the Asian Society for Vascular Biology (ASVB). He has published over 125 papers in international journals including Cir Res, PNAS, JASN, Redox Biology, and has delivered over 70 lectures at the invitation of international and regional scientific societies, institutes and conference organizers. He has received 8109 citations (Google scholar) and his H-index is 49 (Google scholar).

 

Research Interests

  1. Biology of endogenous mediators (e.g. hydrogen sulfide);
  2. Novel functions of Na+/K+ ATPase;
  3. Therapeutic target for pulmonary hypertension.

 

Educational background

1997-2000    Ph. D.     Physiology, the University of Hong Kong.

1990-1993    M. Sci.     Pharmacology, Nanjing Medical University, P. R. China.

1985-1990:   MBBS      Medicine, Xuzhou Medical University, P. R. China.

 

Professional experience

2020.5-present: Acting Chair and Professor in Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, China

2009.01-2020.4: Associate Professor (with Tenure), Department of Pharmacology, Yong Loo Lin school of Medicine, National University of Singapore

2003.10-2008.12:Assistant Professor in Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

2000.5—2003.9: Research Associate and AHA fellow in Section of Molecular Cardiology and Department of Molecular Pharmacology, Albert Einstein College of Medicine, USA

1993.7 – 1997.3: Assistant Professor and lecturer in Department of Pharmacology, School of Basic Medical Science, Nanjing Medical University, China

 

Honors & Awards

2017      Research Excellence Award (AY2015/2016), Yong Loo Lin School of Medicine, National university of Singapore

2001      AHA fellowship, American Heart Association, New York affiliate

2000   Dr. KP Stephen Chang Gold Medal, the University of Hong Kong

2000      Mary Sun Scholarship 1999/2000, the University of Hong Kong

1999      Wong Ching Yee Medical Postgraduate Scholarship, the University of Hong Kong

1999   Prof. A.C. Brown Prize, the 7th Physiology Annual Meeting

1998   Certificate of Merit, the University of Hong Kong.

 

Professional Activities

2010-present   Review Editor & Editorial Board Member, Frontiers in Pharmacology

2010-Present  Review Editor and Editorial Board Member: Frontiers in Clinical and Translational Physiology

2011-present:  Editorial board member, Journal of Pharmacological Sciences

2015-2016:   Reviewing Editor, Antioxidant Redox Signalling

2015-2016:   Lead guest editor, Oxidative Medicine and Cellular Longevity

2010-2011    Associate Editorship, Journal of Alzheimer’s Disease

2010-2012    Editorial Board Member, Biomed Central-Medical Gas Research

2009-present    Editorial Board Member, World Journal of Cardiology

2010-present    Lead guest editor, Journal Biochemistry Research International

2011-present:Editorial board member: World Journal of Hypertension

2010-present    Editorial Board Member, Journal of Geriatric Cardiology

2013-2018    Editor Board Member, Journal of Zhongshan University

 

Selected publications since 2020

1.Nie X*, Shen C, Tan J, Wu Z, Wang W, Chen Y ,Dai Y, Yang X,  Ye S, Chen J, Bian JS*. Periostin: A Potential Therapeutic Target For Pulmonary Hypertension? Circulation Research, 2020, In presss.

[Impact factor:14.86]

2.Zhu M, Cao L, Xiong S, Sun H, Wu Z, Bian JS*. Na+/K+-ATPase-dependent autophagy protects brain against ischemic injury. Signal Transduction and Targeted Therapy. 2020 May 20;5(1):55. doi: 10.1038/s41392-020-0153-7.

[Impact factor: 13.94]

3.Cao X, Cao L, Zhang W, Lu R, Bian JS*, Nie X*. Therapeutic potential of sulfur-containing natural products in inflammatory diseases. Pharmacology & Therapeutics, 2020, Accepted.

[Impact factor:10.557]

4.Sun HJ, Xiong SP, Wu ZY, Cao L, Zhu MY, Moore PK, Bian JS*. Induction of caveolin 3/eNOS complex by nitroxyl (HNO) ameliorates diabetic cardiomyopathy. Redox Biology 2020 May;32:101493. doi: 10.1016/j.redox.2020.101493.

[Impact factor: 9.99]

5.Sun HJ, Cao L, Zhu MY, Wu ZY, Shen CY, Nie XW, Bian JS*. DR-region of Na+/K+-ATPase is a target to ameliorate hepatic insulin resistance in obese diabetic mice. Theranostics. 2020 May 15;10(14):6149-6166. doi: 10.7150/thno.46053. eCollection 2020.

[Impact factor: 8.579]

6.Sun HJ, Wu ZY, Nie XW, Bian JS*. Implications of hydrogen sulfide in liver pathophysiology: mechanistic insights and therapeutic potential. Journal of Advanced Research, 2020, online.

[Impact factor: 6.99]

7.Sun HJ, Lee WT, Leng B, Wu ZY, Yang Y, Bian JS*. Nitroxyl as a Potential Theranostic in the Cancer Arena. Antioxid Redox Signal. 2020 Feb 10;32(5):331-349. doi: 10.1089/ars.2019.7904.

[Impact factor: 6.323]

8.Sun HJ, Wu ZY, Cao L, Zhu MY, Nie XW, Huang DJ, Sun MT, Bian JS*.Role of nitroxyl (HNO) in cardiovascular system: From biochemistry to pharmacology.  Pharmacol Res. 2020 May 29;159:104961. doi: 10.1016/j.phrs.2020.104961

[Impact factor: 5.89]